The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. The FDA grants this designation to investigational medicines intended to treat serious conditions and fill an unmet…
Discussion
Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease. The BEACON study evaluated provider-reported outcomes from 21 investigators treating 162 long-term care patients who received routine…
Discussion
June is Alzheimer’s & Brain Awareness Month, and the Alzheimer’s Association is holding a wide range of events to raise funds to fuel research and promote awareness of Alzheimer’s disease and other forms of dementia. According to the association’s website, …
Becoming educated and informed about Alzheimer’s is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your Alzheimer’s journey.
There is no cure for Alzheimer’s yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
